Theiakou Foteini, Kastanioti Catherine, Zavras Dimitris, Rekkas Dimitrios
Department of Business Administration and Organizations, University of Peloponnese, 24100 Kalamata, Greece.
Department of Public Health Policy, University of West Attica, 11521 Athens, Greece.
Healthcare (Basel). 2025 Jul 30;13(15):1861. doi: 10.3390/healthcare13151861.
: The quality of decision-making processes is increasingly recognized as critical to public trust and policy sustainability. : This narrative review aims to identify and describe process-focused decision support models (DSMs) applied in pharmaceutical policy, and to examine their potential contributions to improving procedural quality in decisions related to pricing, reimbursement, and access to medicines. : Relevant peer-reviewed and gray literature published between 2000 and 2025 was considered, drawing from key databases (e.g., PubMed and Scopus) and international policy reports (e.g., WHO, ISPOR, and HTA agencies). Studies were included if they provided insights into DSMs addressing at least one dimension of decision process quality. : Findings are synthesized narratively and organized by tool type, application context, and key quality dimensions. Frequently referenced tools included the Quality of Decision-Making Orientation Scheme (QoDoS), WHO-INTEGRATE, and AGREE II. QoDoS emerged as the only tool applied across regulatory, HTA, and industry settings, evaluating both individual- and organizational-level practices. WHO-INTEGRATE highlighted equity and legitimacy considerations but lacked a structured format. Overall, most tools demonstrated benefits in promoting internal consistency, transparency, and stakeholder engagement; however, their adoption remains limited, especially in low- and middle-income countries. : Process-focused DSMs offer promising avenues for enhancing transparency, consistency, and legitimacy in pharmaceutical policy. Further exploration is needed to standardize evaluation approaches and expand the use of DSMs in diverse health systems.
决策过程的质量日益被视为对公众信任和政策可持续性至关重要。本叙述性综述旨在识别和描述应用于药品政策的以过程为重点的决策支持模型(DSM),并探讨它们对提高与药品定价、报销和获取相关决策的程序质量的潜在贡献。考虑了2000年至2025年间发表的相关同行评审和灰色文献,这些文献来自关键数据库(如PubMed和Scopus)以及国际政策报告(如世界卫生组织、药物经济学与结果研究协会和卫生技术评估机构)。如果研究提供了对解决决策过程质量至少一个维度的DSM的见解,则将其纳入。研究结果以叙述方式进行综合,并按工具类型、应用背景和关键质量维度进行组织。经常被引用的工具包括决策制定导向质量方案(QoDoS)、世界卫生组织综合工具(WHO-INTEGRATE)和AGREE II。QoDoS是唯一一种应用于监管、卫生技术评估和行业环境的工具,评估个人和组织层面的实践。WHO-INTEGRATE强调公平性和合法性考量,但缺乏结构化格式。总体而言,大多数工具在促进内部一致性、透明度和利益相关者参与方面都显示出益处;然而,它们的采用仍然有限,尤其是在低收入和中等收入国家。以过程为重点的DSM为提高药品政策的透明度、一致性和合法性提供了有前景的途径。需要进一步探索以规范评估方法,并在不同的卫生系统中扩大DSM的使用。